mumps
Enable an AI agent to recognise a possible mumps episode, assess its evidential and clinical state, and identify appropriate clinical and public-health next steps.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to recognise a possible mumps episode, assess its evidential and clinical state, and identify appropriate clinical and public-health next steps.
Mumps is an acute systemic infection caused by the mumps virus (family Paramyxoviridae), classically producing bilateral or unilateral parotitis and capable of orchitis, meningitis, and other glandular or neural complications.
It can be Assemble a mumps episode assessment from symptoms, exposure history and laboratory reports.; Identify missing evidence and propose specimen or diagnostic review under applicable guidance.; Reassess mumps attribution when alternative diagnoses or conflicting results emerge.; Flag recorded manifestations that meet an applicable clinical escalation criterion.; Determine whether reporting, precautions or contact assessment require authorised action.; Track recovery and retain links to persistent complications requiring follow-up..
Distinguishing features
Establish whether the referent is a human infectious-disease episode rather than the MUMPS computing language.
Distinguish observed salivary-gland swelling from an attributed mumps diagnosis: parotitis alone does not establish its cause. [CDC outbreak guidance](https://www.cdc.gov/mumps/php/public-health-strategy/index.html)
Check for laboratory or epidemiological evidence when parotitis is absent; atypical presentations can still qualify as mumps cases. [CDC clinical testing](https://www.cdc.gov/mumps/php/public-health-strategy/mumps-testing-aid.html)
Do not use documented vaccination or a negative laboratory result alone to exclude mumps. [CDC clinical diagnosis](https://www.cdc.gov/mumps/communication-resources/mumps-clinical-diagnosis.html)
Keep a surveillance case classification distinct from a clinician's diagnosis and individual care decisions. [CDC case definition](https://ndc.services.cdc.gov/case-definitions/mumps-2024/)
Scope
+ Episode identity and clinical versus surveillance classification
+ Salivary-gland manifestations and presentations without parotitis
+ Mumps-specific laboratory evidence and interpretation limits
+ Exposure timing, transmission relevance and outbreak relationships
+ Complication surveillance, recovery and unresolved effects
+ Episode-specific clinical and public-health action decisions
- MUMPS programming language and database systems
- Mumps virus taxonomy, genome and laboratory isolate management
- The person's complete longitudinal health record
- Vaccine product specifications and vaccination programme management
- Outbreak-wide transmission analysis and contact-tracing operations
- Independent models of alternative causes of parotitis or organ complications
Characteristics
- Clinical attribution
- suspected | supported | clinician-diagnosed | alternative diagnosis favoured | unresolved Expresses the current interpretation without equating gland swelling with confirmed mumps.
- Surveillance classification
- Classification label with authority, case-definition version and assessment date; unassessed permitted Makes reporting decisions interpretable under the applicable rules.
- Salivary-gland involvement
- Affected gland, left | right | bilateral, swelling and tenderness present | absent | unknown Records the characteristic presentation without making it mandatory.
- Episode timing
- Dates or bounded date intervals for exposure, first symptoms, gland swelling and resolution Supports temporal compatibility, specimen interpretation and precautions.
- Mumps test evidence
- Linked laboratory report with method, specimen, collection time, result and interpretation Allows evidence to be assessed in its collection context.
- Vaccination context
- Linked documented mumps-containing vaccine doses and dates, or unknown history Provides relevant context without treating vaccination as exclusion of disease.
- Epidemiological linkage
- Linked exposure, case or outbreak with contact setting, dates and strength of evidence Separates plausible exposure from demonstrated transmission.
- Complication assessment
- For each assessed complication: absent | suspected | established | resolving | residual | not assessed Keeps complication recognition distinct from uncomplicated gland symptoms.
- Transmission precaution status
- assessment pending | indicated | active | ended, with governing guidance and timing basis Supports reviewable precautions independently of diagnostic certainty.
- Recovery state
- active illness | improving | symptoms resolved | persistent effects | follow-up unknown Prevents administrative closure from being mistaken for clinical recovery.
Also called
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.mumps
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 7 bundles · 13 layers · 20 findings · 41 questions.
Mumps episode attribution Establishes what episode is being represented and why mumps is being considered.
Neither the registry label nor salivary-gland swelling alone establishes an episode of mumps.
Referent and episode
Separates disease meaning, current illness and historical mentions.
Disease episode boundary
Record the evidence identifying a human disease episode and its relationship to earlier illness.
- Does this record concern suspected human mumps, past mumps, exposure alone or a computing referent? definition
- What establishes that these observations belong to one episode rather than separate or recurrent illnesses? boundary
Attribution and alternatives
Separates clinical interpretation, competing explanations and surveillance labels.
Mumps attribution basis
Retain the reasoning behind mumps attribution and any separate surveillance classification.
- Which observations, test results or epidemiological links support mumps, and who assessed them? provenance
- Which alternative explanations for gland swelling or other manifestations remain plausible? boundary
- Which authority and definition version govern any recorded surveillance classification? provenance
Mumps manifestation course Represents salivary-gland findings, other symptoms and their chronology.
An agent needs the actual presentation and its timing, including presentations without recorded parotitis.
Salivary-gland pattern
Characterises observed swelling rather than assuming all jaw or neck swelling is parotitis.
Gland involvement
Record anatomical localisation, laterality, tenderness and the basis of observation.
- Which salivary glands are affected, on which side, and is swelling observed, reported, absent or unassessed? measurement
- What examination distinguishes gland swelling from lymph-node enlargement, dental disease or another local process? boundary
Symptom chronology
Places the clinical presentation on an explicit episode timeline.
Onset and evolution
Keep first symptoms, gland-swelling onset and subsequent change separately identifiable.
- When did the first symptoms and any gland swelling begin, and how uncertain are those dates? measurement
- What fever, pain, intake limitation or other symptoms accompanied the episode and how have they changed? measurement
- If parotitis is absent, which manifestation or evidence triggered the mumps assessment? provenance
Mumps diagnostic evidence Makes specimen context, laboratory findings and uncertainty available for reassessment.
Mumps test interpretation depends on specimen timing and clinical context. [CDC laboratory testing](https://www.cdc.gov/mumps/php/laboratories/index.html)
Specimen and assay
Connects each result to the material collected and the test performed.
Traceable mumps test
Preserve the original laboratory result with collection and processing context.
- Which method and specimen produced this result, and where is the original laboratory report? provenance
- How long after symptom or gland-swelling onset was the specimen collected? measurement
- Were specimen adequacy, transport or assay limitations recorded? provenance
Evidence interpretation
Combines laboratory findings with presentation, vaccination and exposure evidence.
Diagnostic uncertainty
Record what each result supports, what it fails to settle and what evidence would change the assessment.
- How do collection timing, vaccination history and epidemiological linkage affect interpretation of the result? boundary
- What explains any disagreement between laboratory evidence and clinical suspicion? boundary
- Would additional sampling, alternative-cause testing or specialist review resolve a decision-relevant uncertainty? action
Mumps exposure and transmission Relates the episode to preceding exposure and potential onward exposure.
Exposure compatibility and precaution decisions require distinct time intervals and evidence of contact.
Acquisition context
Records plausible acquisition settings without assigning an unsupported source.
Exposure link strength
Represent contact dates, settings and the evidential strength of case or outbreak links.
- Which contacts or shared settings preceded illness, and are their dates compatible with the incubation interval in the cited guidance? measurement
- Is each source-case or outbreak link documented, inferred or merely possible? provenance
Onward exposure window
Records the guideline-derived period relevant to precautions and contact assessment.
Transmission window assessment
Keep the operational exposure window and its assumptions separate from claims of observed transmission.
- Which guidance and onset date anchor the potential infectious interval for this episode? provenance
- Which household, school, workplace or healthcare encounters occurred within that interval? measurement
- How should the interval be assessed when parotitis is absent or its onset is uncertain? action
Mumps complications and recovery Tracks assessed complications, escalation needs and episode outcome.
Resolution of gland swelling is insufficient to describe the state of every suspected mumps episode.
Organ complication assessment
Records assessment of manifestations such as testicular, neurological, auditory or pancreatic involvement.
Complication evidence and urgency
Separate symptoms suggesting organ involvement from established complications and their attribution to mumps.
- Which possible complications were assessed, and what supports or contradicts each assessment? measurement
- Is the relationship of each complication to mumps established, suspected or unresolved? boundary
- Do recorded symptoms meet a cited clinical escalation criterion, and has the responsible clinician been alerted? action
Resolution and residual effects
Separates symptom improvement, persistent effects and incomplete follow-up.
Episode outcome
Record recovery evidence and transfer persistent problems to linked clinical models.
- Which symptoms have resolved, which persist, and when was each last assessed? measurement
- Which residual problems require continuing follow-up or a linked complication model? action
- Does episode closure reflect documented recovery or only an end to available observations? boundary
Mumps response decisions Connects episode evidence to accountable clinical and public-health actions.
Action eligibility can depend on suspicion, setting and local guidance before diagnostic uncertainty is resolved.
Precautions and reporting
Makes the basis and completion state of mumps control actions explicit.
Applicable control actions
Record applicable isolation, attendance, reporting and contact-assessment decisions with their authority.
- Which jurisdictional and setting-specific guidance governs precautions and notification for this episode? provenance
- Which actions are indicated, who is authorised to perform them, and which have been completed? action
- What evidence and timing permit precautions or attendance restrictions to end? action
Clinical and prevention handoffs
Links ongoing care and vaccination-context review to the responsible services.
Episode follow-up plan
Record the clinician-approved care plan and any public-health-directed prevention review.
- What symptom-management and reassessment plan has the responsible clinician established? action
- Does documented vaccination history or outbreak guidance require referral for prevention review? action
- Which pending test, complication assessment or public-health decision must be resolved before follow-up ends? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- classic epidemic parotitis (wild-type mumps)
- vaccine-associated or vaccine-strain mumps-like illness
- breakthrough mumps in previously vaccinated persons
- clinically inapparent (subclinical) mumps
- mumps orchitis / oophoritis as a presenting or dominant form
- mumps meningitis / encephalitis
- mumps pancreatitis
- laboratory-confirmed versus epidemiologically linked versus clinically compatible case
- Which of these kinds and varieties hold for the sense of mumps this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Wikidata - Q176741 - item for the disease mumps
- ICD-10 - B26, B26.0-B26.9 - mumps and specified complications
- ICD-11 - 1D80 - mumps
- MeSH - D009107 - Mumps
- SNOMED CT - 36989005 - Mumps (disorder)
- NCBI Taxonomy - 11269 - Mumps virus (MuV); also classified as Orthorubulavirus parotitidis in ICTV
- ICTV - Orthorubulavirus parotitidis - species name of the mumps virus
- Which of these identifiers and schemes hold for the sense of mumps this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- WHO: mumps as a vaccine-preventable disease; two-dose MMR/MMRV recommended in many national schedules (WHO position paper on mumps vaccines)
- CDC / CSTE (United States): mumps is a nationally notifiable condition; clinical, laboratory, and epidemiologic case definitions
- FDA / EMA and national regulators: licensure and strain specifications for live attenuated mumps vaccines (Jeryl Lynn, RIT 4385, Leningrad-Zagreb, Urabe, etc.)
- IHR / national communicable-disease laws: outbreak reporting and isolation of infectious cases during the infectious period
- Which of these standards and regulation hold for the sense of mumps this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Childhood and adolescent immunization with MMR or MMRV, typically two doses
- Outbreak investigation in schools, universities, military barracks, and other close-contact settings
- Clinical diagnosis of parotitis with laboratory confirmation (RT-PCR, IgM) when measles/mumps/rubella surveillance requires it
- Differential diagnosis of acute parotitis, orchitis, aseptic meningitis, and pancreatitis
- Public-health case counting, isolation, and catch-up vaccination during campus or community outbreaks
- Which of these real-world use hold for the sense of mumps this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- incubation period - 12-25 (usually 16-18) - days
- infectious period (relative to parotitis onset) - from 2 days before to 5 days after - days
- clinical attack showing parotitis among infections - about 30-40 subclinical; majority of symptomatic cases have parotitis - proportion of infections
- orchitis in post-pubertal males with mumps - 15-30 - %
- aseptic meningitis as a complication - 1-10 - %
- two-dose MMR effectiveness against mumps - approximately 86-88 (lower in intense outbreak settings) - %
- virus particle size - 100-600 (typically ~200) - nm
- Which of these typical measurements hold for the sense of mumps this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Orchitis, oophoritis, mastitis, pancreatitis, meningitis, encephalitis, hearing loss, and (rarely) death
- Misdiagnosis of bacterial parotitis, sialolithiasis, or other viral parotitis as mumps (or the reverse)
- Vaccine failure and waning immunity leading to breakthrough outbreaks in highly vaccinated populations
- Adverse events historically associated with some vaccine strains (e.g., aseptic meningitis with Urabe and Leningrad-Zagreb in some programmes)
- False-negative PCR late after onset; IgM false positives and cross-reactivity
- Congenital concerns are far lower than for rubella, but infection in pregnancy is still managed as a risk
- Which of these failure modes and hazards hold for the sense of mumps this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- United States and much of Europe: two-dose MMR; mumps now mainly seen as campus/occupational outbreaks in vaccinated young adults
- Japan historically used a monovalent mumps vaccine and has had different strain and coverage debates than MMR countries
- Some countries still use Urabe or Leningrad-Zagreb strains; others (US, much of EU) use Jeryl Lynn or derived RIT 4385
- In under-vaccinated regions, mumps remains a classic childhood epidemic disease rather than a breakthrough-outbreak disease
- Case notification and laboratory confirmation rates vary widely; many countries do not routinely confirm sporadic parotitis
- Which of these regional variation hold for the sense of mumps this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- acute bacterial parotitis / sialadenitis - usually unilateral, toxic, often with purulent duct discharge and neutrophilia; mumps is often bilateral, viral-prodrome, and not purulent
- sialolithiasis (salivary stone) - recurrent meal-related swelling of one gland, often with a palpable or imaging-visible stone; not epidemic and not systemic
- other viral parotitis (influenza, parainfluenza, EBV, CMV, coxsackie, HIV) - clinically similar parotid swelling; distinguished by mumps-specific RT-PCR or paired serology, not by gland exam alone
- measles - morbilliform rash, Koplik spots, cough/coryza/conjunctivitis; measles virus vs mumps virus on PCR
- rubella - milder rash illness, lymphadenopathy; rubella-specific serology/PCR; both share MMR vaccine, not the same virus
- mumps vaccine (live attenuated virus) - the immunizing product versus the wild disease; vaccine-strain can rarely cause mumps-like illness and is identified by strain genotyping
- acute HIV infection or other causes of aseptic meningitis/orchitis - no parotitis required; HIV Ag/Ab or viral load, and mumps PCR/serology, separate the syndromes
- Which of these neighbouring kinds and how to tell them apart hold for the sense of mumps this model covers, and on what evidence? provenance
Sources
- Mumps - WHO disease description, virus family, and vaccine-preventable-disease framing
- Mumps - Clinical picture, complications, and public-health case use in the United States
- Mumps (Pink Book) - Incubation, infectious period, complications, and vaccine history
- Mumps virus vaccines: WHO position paper - Vaccine strains, two-dose policy, and outbreak control
What the second pass must settle
- Does authoritative registry context confirm that vr.tr.mumps denotes the infectious disease, and does an existing world model already own this concept?
- Should asymptomatic laboratory-confirmed infection be represented as an episode within this model or through a linked infection model?
- Which jurisdictional case definitions, notification rules and setting-specific precaution guidance must the initial publication support?
- What evidence should distinguish prolonged illness, recurrent parotitis and a separate mumps episode?
- Which validated escalation and follow-up criteria should govern complication assessment, especially when parotitis is absent?